Chemotherapy has dominated the cancer management landscape despite the emergence of new therapeutics regimes. Although a number of chemotherapy drugs are available, their widespread use is mainly limited due to their adverse side effects and drug resistance.
Chemotherapy has dominated the cancer management landscape despite the emergence of new therapeutics regimes. Although a number of chemotherapy drugs are available, their widespread use is mainly limited due to their adverse side effects and drug resistance. Researchers have indulged in extensive research and development activities to increase the efficacy of cytotoxic drugs, such as combining different chemotherapeutic drugs. However, systemic toxicity and narrow therapeutic window limit their clinical use. However, the introduction of monoclonal antibodies has provided opportunity to use their specific binding property for targeted drug delivery. To date, a cocktail of therapeutic monoclonal antibodies have gained approval for the management of several cancers.
“Global Cancer Antibody Drug Conjugate Market USD 30 Billion Opportunity “
Download Report: https://www.kuickresearch.com/report-global-cancer-antibody-drug-conjugate-market
“Global Bispecific Antibody Market USD 20 Billion Opportunity”
Download Report: https://www.kuickresearch.com/report-global-bispecific-antibodies-antibody-market-size-blincyto-hemlibra-rybrevant-sales
“Global Trispecific Antibody Market USD 2 Billion Opportunity”
Download Report: https://www.kuickresearch.com/report-trispecific-antibody-antibodies-market-clinical-trials-development-companies
To further enhance the efficacy of chemotherapeutic drugs and to mitigate the challenges associated with them, researchers have also designed novel antibody drug conjugates (ADC). The ADC comprises of cytotoxic agent attached to antibody which targets specific tumor antigen. This novel approach combines the targeted delivery of antibody with the tumor killing potential of the payload, which is generally too toxic to be systemically administered. Currently, 15 antibody drug conjugates have entered the global market which is indicated mainly for the management of hematological malignancies. Moreover, the pipeline of novel antibody drug conjugate is highly crowded and consists of more than 50 drugs in clinical pipeline which are expected to enter the market during the forthcoming years.
Further, the continuous research activities and surge in demand of enhanced therapeutic drugs, researchers have also designed more advanced bispecific and trispecific antibody constructs which can bind two or more antigens simultaneously. To date, only two bispecific antibodies including Blincyto and Rybrevant have entered the market which has shown encouraging sales in the global market owing to their novel mechanism of action. In addition, several bispecific antibodies have gained fast track designation, orphan drug designation, and breakthrough therapy designation which suggests promising future of this segment during the forecast period.
At present, no trispecific antibody has gained entry into market for the management of cancer. However, several trispecific antibodies have entered the initial stages of clinical development and have shown encouraging preliminary results. The major drugs in the clinical pipeline include GTB3550, GTB4550, HPN424, SAR443216, HPN217, and several others. GTB-3550 developed by GT Biopharma is one of the most promising Trike product candidates being initially developed for the treatment of acute myeloid leukemia, myelodysplastic syndrome, and other CD33+ hematologic cancers.
The global cancer antibody market is highly competitive and consists of several key players which actively invest in research and development sector. The major key players in the market include Pfizer, Roche, Genmab, Xencor, Novartis, AstraZencea, Abbvie, and others. Companies in the cancer antibodies market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. For instance, in September 2020, AbbVie and I-Mab entered into a strategic partnership for the development and commercialization of lemzoparlimab (also known as TJC4), which is a monoclonal antibody drug used to treat multiple cancers.
As per our reports findings, the global cancer antibody market is expected to witness exponential growth by 2028. The considerable rise in the geriatric population along with shift towards sedentary lifestyle increases the risk of developing the cancer. Moreover, the unavailability of effectively curing drugs and the rate at which conventional therapies are failing possess an unmet need for the development of targeted therapies which will boost the growth of the market. In addition to this, the rising funding by the government as well as private sectors also increases the research and development activities in this area.
For More Information Related To Report Contact:
Neeraj Chawla
Research Head
Kuick Research
+919810410366